MoonLake Immunotherapeutics (MLTX) Invested Capital (2021)

MoonLake Immunotherapeutics' (MLTX) quarterly Invested Capital came in at $15.0 million in Q4 2021.

MoonLake Immunotherapeutics (MLTX) Invested Capital (2021) Analysis & Trends

MoonLake Immunotherapeutics' Invested Capital history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2021.

  • On a quarterly basis, Invested Capital changed N/A year-over-year to $15.0 million in Q4 2021; TTM through Sep 2022 was $15.0 million, a N/A change from a year earlier, with the FY2021 full-year figure at $15.0 million, changed N/A from the prior year.
  • Invested Capital was little changed at $15.0 million in Q4 2021 per MLTX's latest filing.
  • Across five years, Invested Capital topped out at $15.0 million in Q4 2021 and bottomed at $15.0 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 116.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 MoonLake Immunotherapeutics 1.38 Bn 1.02 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 15.00 Mn